ORKA — Oruka Therapeutics, Inc. stock price, charts and financials

Latest market price

98.13

+3.34+3.52%

Overview Short InterestFilings

ORKAQT92Oruka Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

98.13+3.52%

News

Up 3.5% — Oruka Therapeutics Is Priced For Perfection - It's Time To Cash Out (SeekingAlpha).

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TNGX+7.90%$29.36 RCUS+4.27%$28.80 LEGN+0.63%$19.13 DNLI+4.41%$24.17 VKTX+1.01%$32.94 CPRX+0.00%$31.49 TLX+2.69%$10.29 ADPT+6.23%$24.55

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	28.62%	Shs Outstand	37.45M	Perf Week	8.49%

Market Cap	3.68B	Forward P/E	-	EPS next Y	-2.51	Insider Trans	-35.37%	Shs Float	26.48M	Perf Month	18.04%

Enterprise Value	3.29B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	33.36%	Perf Quarter	47.65%

Income	-105.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	4.97	Perf Half Y	186.09%

Sales	0.00	P/B	7.55	EPS next Y	-19.01%	ROA	-23.04%	Short Interest	8.83M	Perf YTD	223.75%

Book/sh	13.00	P/C	9.45	EPS next 5Y	-	ROE	-25.99%	52W High	99.00 -0.88%	Perf Year	621.54%

Cash/sh	10.39	P/FCF	-	EPS past 3/5Y	-	ROIC	-27.31%	52W Low	12.84 664.25%	Perf 3Y	300.86%

Dividend Est.	19.36 (19.72%)	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	7.04% 5.90%	Perf 5Y	174.41%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	61.12%	Oper. Margin	0.00%	ATR (14)	5.49	Perf 10Y	-84.55%

Dividend Ex-Date	Aug 29, 2024	Quick Ratio	23.76	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	63.24	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	23.76	EPS Q/Q	-20.00%	SMA20	8.28%	Beta	-0.38	Target Price	153.25

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	23.54%	Rel Volume	0.45	Prev Close	94.79

Employees	68	LT Debt/Eq	0.00	Earnings	Aug 10	SMA200	97.43%	Avg Volume	1.38M	Price	98.13

IPO Date	Aug 08, 1997	Option/Short	Yes / Yes	EPS/Sales Surpr.	12.24% -	Net Debt/EBITDA	0.41	Volume	621,227	Change	3.52%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-01-26	Reiterated	UBS	Buy	$100 → $130
Jun-02-26	Reiterated	Piper Sandler		$75 → $180
Apr-30-26	Reiterated	Leerink Partners	Outperform	$109 → $120
Apr-29-26	Reiterated	HC Wainwright & Co.	Buy	$40 → $120
Apr-28-26	Reiterated	UBS	Buy	$50 → $100
Apr-27-26	Reiterated	Wedbush	Outperform	$85 → $165
Apr-27-26	Reiterated	Guggenheim	Buy	$125 → $200
Apr-27-26	Reiterated	BTIG	Buy	$73 → $151
Apr-15-26	Reiterated	Wedbush	Outperform	$45 → $85
Mar-13-26	Reiterated	BTIG	Buy	$73

Latest News

Aug-03-26

Aug-03-2605:40PM

Oruka Therapeutics Is Priced For Perfection - It's Time To Cash OutSeekingAlpha

Jul-10-26

Jul-10-2603:58PM

Oruka Therapeutics - Intriguing Long Acting Psoriasis Programs May Need Further DeriskingSeekingAlpha

Jul-02-26

Jul-02-2602:30AM

Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million SharesBenzinga

Jun-27-26

Jun-27-2603:28PM

Oruka Stock Is Now Up Nearly 700%. Here's What a $687,000 Insider Sale Could Meanfool.com

Jun-23-26

Jun-23-2606:47AM

HC Wainwright & Co. Reiterates Buy on Oruka Therapeutics, Maintains $120 Price TargetBenzinga

Jun-22-26

Jun-22-2612:08PM

Apogee Therapeutics, Definium Therapeutics, Baldwin Insurance And Other Big Stocks Moving Higher On MondayBenzinga

Jun-10-26

Jun-10-2601:55PM

Wall Street Analysts Believe Oruka Therapeutics, Inc. (ORKA) Could Rally 111.13%: Here's is How to TradeYahoo

Company

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018	FY 2017 12/31/2017
Total Revenue	0	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0	0	0
Selling, General and Administrative Excl. Other	21	13	6	5	5	5	4	4	5
Research and Development	101	75	1	4	14	5	2	4	14
Other Operating Expense	0	0	0	1	0	0	0	0	0
Operating Income	-122	-88	-7	-10	-19	-10	-6	-8	-19
Interest Expense	0	1	0	0	0	0	0	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	17	6	2	0	0	0	0	0	0
Net Income Before Taxes	-105	-84	-5	-10	-19	-10	-6	-8	-19
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-105	-84	-5	-10	-19	-10	-5	-8	-18
Net Income From Continuing Operations	-105	-84	-5	-10	-19	-10	-5	-8	-18
Net Income	-105	-84	-5	-10	-19	-10	-5	-8	-18
EPS (Recurring)	-2.31	-4.99	-4.44	-8.27	-16.68	-8.40	-49.79	-123.73	-382.87
EPS (Basic, Before Extraordinaries)	-2.31	-4.99	-4.44	-8.27	-16.68	-8.40	-49.79	-123.73	-382.87
EPS (Diluted)	-2.31	-4.99	-4.44	-8.27	-16.68	-8.40	-49.79	-123.73	-382.87
EBITDA	-105	-82	-5	-10	-19	-10	-6	-8	-19
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	46	17	14	14	14	5	0	0	0
Market Capitalization	1,394	330	286	398	361	241	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Goncalves Joana	Chief Medical Officer	Jul 15 '26	Sale	86.28	7,000	603,937	32,718	Jul 15
Goncalves Joana	Chief Medical Officer	Jul 15 '26	Option Exercise	7.32	7,000	51,240	39,718	Jul 15
Agarwal Arjun	Senior Vice President, Finance	Jul 13 '26	Option Exercise	15.69	9,999	156,904	25,311	Jul 13
Agarwal Arjun	Senior Vice President, Finance	Jul 13 '26	Sale	84.63	9,999	846,180	15,312	Jul 13
Fairmount Funds Management LLC	director, 10 percent owner:	Jul 01 '26	Sale	84.43	3,553,410	300,014,406	1,131,954	Jul 01
Sandler Laura Lee	Chief Operating Officer	Jul 01 '26	Option Exercise	7.80	5,000	39,000	241,384	Jul 01
Sandler Laura Lee	Chief Operating Officer	Jul 01 '26	Sale	94.42	5,000	472,079	236,384	Jul 01
Agarwal Arjun	Senior Vice President, Finance	Jun 22 '26	Sale	80.95	1,587	128,468	15,312	Jun 22
Goncalves Joana	Chief Medical Officer	Jun 15 '26	Sale	69.28	7,947	550,606	32,718	Jun 15
Klein Lawrence Otto	Chief Executive Officer	Jun 15 '26	Sale	69.69	1,729	120,494	925,580	Jun 15
Sandler Laura Lee	Chief Operating Officer	Jun 15 '26	Sale	69.69	600	41,814	236,384	Jun 15
Quinlan Paul T	General Counsel	Jun 15 '26	Sale	69.69	733	51,083	31,034	Jun 15
Agarwal Arjun	Senior Vice President, Finance	Jun 15 '26	Sale	69.69	395	27,528	16,899	Jun 15
Goncalves Joana	Chief Medical Officer	Jun 15 '26	Option Exercise	7.32	7,000	51,240	40,665	Jun 15
Agarwal Arjun	Senior Vice President, Finance	Jun 12 '26	Sale	69.72	9,459	659,508	17,294	Jun 15

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.